Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC

摘要

Brentuximab vedotin (BV) is an antibody-drug conjugate (ADC) composed of a CD30-directed monoclonal antibody covalently linked to the anti-microtubule agent monomethyl auristatin E (MMAE). Binding of the ADC to CD30 on the cell surface initiates internalization of the MMAE-CD30 complex, followed by proteolytic cleavage that releases MMAE directly inside the tumor. BV has proven efficacy in patients with relapsed/refractory Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL), particularly in the setting of anaplastic lymphoma kinase positive (ALK+) ALCL [1]. Promising activity has also been seen in other CD30-expressing (CD30+) non-Hodgkin lymphomas (NHL), including cutaneous T-cell lymphoma (CTCL) subtypes such as cutaneous anaplastic T cell lymphoma and transformed mycosis fungoides (tMFs) [2,3], as well as CD30+ peripheral T-cell lymphoma (PTCL) [4,5]